Callio Therapeutics 任命 Chris Hassig 为新任首席科学官
STAT+: Up and down the ladder: The latest comings and goings
Callio Therapeutics 任命 Chris Hassig 为首席科学官。Hassig 此前在 Boundless Bio 担任相同职务。该信息来自 STAT 的每周人事动态专栏,未提供其他临床或监管数据。
![]()
By Ed Silverman
Oct. 23, 2026
Pharmalot Columnist, Senior Writer
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.
And here is our regular feature in which we highlight a different person each week. This time around, we note that Callio Therapeutics hired Chris Hassig as chief scientific officer. Previously, he held the same role at Boundless Bio.

But all work and no play can make for a dull chief scientific officer.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT Pharma 医药频道 · statnews.com